ZNTL
Zentalis Pharmaceuticals, Inc.
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | 0 | 67.4M | 0 | 0 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Expenses | ||||
| R&D Expenses | — | — | — | — |
| SG&A Expense | — | — | — | — |
| Total Op. Expenses | — | — | — | — |
| Operating Income | -152.8M | -191.2M | -299.5M | -227.3M |
| EBITDA | — | — | — | — |
| Below the Line | ||||
| Interest Expense | — | — | — | — |
| Pre-Tax Income | — | — | — | — |
| Income Tax | — | — | — | — |
| Net Income | -137.1M | -165.8M | -292.2M | -236.8M |
| Per Share | ||||
| EPS (basic) | — | — | — | — |
| EPS (diluted) | — | — | — | — |
| Shares | ||||
| Basic Shares | — | — | — | — |
| Diluted Shares | 72M | 71M | 65M | 53M |